Healthcare provider profile · identity verified

Qiong Wu, MD

Allopathic & Osteopathic Physicians|General Practice · FLUSHING, NY · NPI 1992763916

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Qiong Wu, MD received $666.59 in general payments during 2025 across 18 reported records.

Gilead Sciences, Inc. accounted for 60.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Vemlidy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$666.59

18 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Gilead Sciences, Inc.	Unresolved — no canonical attribution shown	$399.97	60.0%	16	2025
Madrigal Pharmaceuticals	Unresolved — no canonical attribution shown	$141.62	21.2%	1	2025
Bayer Healthcare Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$125.00	18.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$666.59	18

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
REZDIFFRA Normalized: rezdiffra	Drug	Madrigal Pharmaceuticals	$141.62	1	2025
Source payment records 2025-12-16 · Madrigal Pharmaceuticals · $141.62 · Open Payments source
Kerendia Normalized: kerendia	Drug	Bayer Healthcare Pharmaceuticals Inc.	$125.00	1	2025
Source payment records 2025-06-19 · Bayer Healthcare Pharmaceuticals Inc. · $125.00 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Gilead Sciences, Inc. Exact reporting entity; no affiliate inference	2025	Vemlidy open payments reported associated product	CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906	Vemlidy · 2024 Exact normalized brand match · 1 Part D row	153	15

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1161	241
Amlodipine Besylate	Amlodipine Besylate	1072	194
Losartan Potassium	Losartan Potassium	761	151
Metoprolol Succinate	Metoprolol Succinate	613	123
Vascepa	Icosapent Ethyl	596	92
Metformin Hcl	Metformin Hcl	554	112
Simvastatin	Simvastatin	496	86
Tamsulosin Hcl	Tamsulosin Hcl	459	84
Omeprazole	Omeprazole	381	130
Diclofenac Epolamine	Diclofenac Epolamine	333	92
Raloxifene Hcl	Raloxifene Hcl	294	45
Azithromycin	Azithromycin	274	177
Glimepiride	Glimepiride	271	45
Enalapril Maleate	Enalapril Maleate	233	40
Januvia	Sitagliptin Phosphate	233	38
Metformin Hcl Er	Metformin Hcl	209	34
Jardiance	Empagliflozin	202	28
Alendronate Sodium	Alendronate Sodium	197	41
Trazodone Hcl	Trazodone Hcl	184	50
Fluticasone Propionate	Fluticasone Propionate	169	67
Vemlidy	Tenofovir Alafenamide	153	15
Celecoxib	Celecoxib	145	79
Metoprolol Tartrate	Metoprolol Tartrate	140	24
Ammonium Lactate	Ammonium Lactate	132	62
Clopidogrel	Clopidogrel Bisulfate	132	27
Finasteride	Finasteride	125	25
Synthroid	Levothyroxine Sodium	124	23
Montelukast Sodium	Montelukast Sodium	122	33
Fluocinonide	Fluocinonide	115	68
Alcohol Prep Pads	Alcohol Antiseptic Pads	114	46
Levothyroxine Sodium	Levothyroxine Sodium	106	20
Clobetasol Propionate	Clobetasol Propionate	105	46
Meclizine Hcl	Meclizine Hcl	102	56
Donepezil Hcl	Donepezil Hcl	98	17
Cromolyn Sodium	Cromolyn Sodium	95	45
Lidocaine-Prilocaine	Lidocaine/Prilocaine	94	45
Xarelto	Rivaroxaban	89	12
Chlorhexidine Gluconate	Chlorhexidine Gluconate	86	40
Gemfibrozil	Gemfibrozil	86	13
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	86	20
Eliquis	Apixaban	84	16
Triamcinolone Acetonide	Triamcinolone Acetonide	84	44
Zolpidem Tartrate	Zolpidem Tartrate	82	31
Rosuvastatin Calcium	Rosuvastatin Calcium	81	16
Valsartan	Valsartan	81	21
Memantine Hcl	Memantine Hcl	79	12
Icosapent Ethyl	Icosapent Ethyl	78	38
Lisinopril	Lisinopril	77	16
Promethazine Hcl	Promethazine Hcl	77	55
Ciprofloxacin Hcl	Ciprofloxacin Hcl	74	61
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	74	21
Mupirocin	Mupirocin	73	45
Pioglitazone Hcl	Pioglitazone Hcl	71	14
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	71	11
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	70	37
Atenolol	Atenolol	66	13
Vitamin D2	Ergocalciferol (Vitamin D2)	66	49
Albuterol Sulfate Hfa	Albuterol Sulfate	65	30
Hydrochlorothiazide	Hydrochlorothiazide	64	17
Isosorbide Mononitrate Er	Isosorbide Mononitrate	63	13
Nitroglycerin	Nitroglycerin	63	27
Esomeprazole Magnesium	Esomeprazole Magnesium	58	17
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	58	12
Hydrocortisone	Hydrocortisone	56	34
Carvedilol	Carvedilol	53	12
Diclofenac Sodium	Diclofenac Sodium	53	31
Farxiga	Dapagliflozin Propanediol	53	suppressed
Nifedipine Er	Nifedipine	53	suppressed
Amoxicillin	Amoxicillin	52	41
Tradjenta	Linagliptin	50	suppressed
Loperamide	Loperamide Hcl	49	40
Furosemide	Furosemide	48	11
Gabapentin	Gabapentin	48	30
Olmesartan Medoxomil	Olmesartan Medoxomil	46	suppressed
Pravastatin Sodium	Pravastatin Sodium	46	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	45	44
Acarbose	Acarbose	45	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	44	11
Solifenacin Succinate	Solifenacin Succinate	40	suppressed
Glipizide Er	Glipizide	39	11
Lidocaine	Lidocaine	39	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	38	11
Mometasone Furoate	Mometasone Furoate	38	19
Rybelsus	Semaglutide	37	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	36	suppressed
Famotidine	Famotidine	35	suppressed
Mupirocin	Mupirocin Calcium	35	24
Procto-Med Hc	Hydrocortisone	35	20
Alcohol Pads	Alcohol Antiseptic Pads	34	20
Glipizide	Glipizide	34	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Ranolazine Er	Ranolazine	33	suppressed
Fenofibrate	Fenofibrate,micronized	32	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	32	19
Halobetasol Propionate	Halobetasol Propionate	29	15
Latanoprost	Latanoprost	29	suppressed
Colchicine	Colchicine	28	13
Ciclopirox	Ciclopirox	26	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	24	14
Repaglinide	Repaglinide	24	suppressed
Allopurinol	Allopurinol	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Proctozone-Hc	Hydrocortisone	23	suppressed
Meloxicam	Meloxicam	22	13
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Ursodiol	Ursodiol	21	suppressed
Azelastine Hcl	Azelastine Hcl	20	suppressed
Bepotastine Besilate	Bepotastine Besilate	20	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	19	17
Entecavir	Entecavir	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Creon	Lipase/Protease/Amylase	17	suppressed
Folic Acid	Folic Acid	17	suppressed
Linzess	Linaclotide	17	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	16	suppressed
Invokana	Canagliflozin	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Primidone	Primidone	15	suppressed
Steglatro	Ertugliflozin Pidolate	15	suppressed
Tacrolimus	Tacrolimus	15	suppressed
Admelog Solostar	Insulin Lispro	13	suppressed
Carbamazepine Er	Carbamazepine	13	suppressed
Ciprofloxacin-Dexamethasone	Ciprofloxacin Hcl/Dexameth	13	suppressed
Clotrimazole	Clotrimazole	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Nateglinide	Nateglinide	13	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Entacapone	Entacapone	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Pro Comfort Alcohol Pads	Alcohol Antiseptic Pads	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Digoxin	Digoxin	11	suppressed
Multaq	Dronedarone Hcl	11	suppressed
Naproxen	Naproxen	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	11	suppressed
Restasis	Cyclosporine	11	suppressed
Scopolamine	Scopolamine	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$666.59 · 18 records	Gilead Sciences, Inc.	Kerendia, REZDIFFRA	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error